Hannah J Anderson1, Deni S Galileo2,3. 1. Department of Biological Sciences, University of Delaware, Newark, DE, 19716, USA. 2. Department of Biological Sciences, University of Delaware, Newark, DE, 19716, USA. dgalileo@udel.edu. 3. Helen F. Graham Cancer Center and Research Institute, Christiana Care Health System, Newark, DE, 19713, USA. dgalileo@udel.edu.
Abstract
PURPOSE: The cell adhesion/recognition protein L1CAM (L1; CD171) has previously been shown to act through integrin, focal adhesion kinase (FAK) and fibroblast growth factor receptor (FGFR) signaling pathways to increase the motility and proliferation of glioblastoma cells in an autocrine/paracrine manner. Here, we investigated the effects of clinically relevant small-molecule inhibitors of the integrin, FAK and FGFR signaling pathways on glioblastoma-derived cells to determine their effectiveness and selectivity for diminishing L1-mediated stimulation. METHODS: The effects of the FGFR inhibitor PD173074, the FAK inhibitors PF431396 and Y15 and the αvβ3/αvβ5 integrin inhibitor cilengitide were assessed in L1-positive and L1-negative variants of the human glioblastoma-derived cell lines T98G and U-118 MG. Their motility and proliferation were quantified using time-lapse microscopy and DNA content/cell cycle analyses, respectively. RESULTS: The application of all four inhibitors resulted in reductions in L1-mediated motility and proliferation rates of L1-positive glioblastoma-derived cells, down to the level of L1-negative cells when used at nanomolar concentrations, whereas no or much smaller reductions in these rates were obtained in L1-negative cells. In addition, we found that single inhibitor treatment resulted in maximum effects (i.e., combinations of FAK or integrin inhibitors with the FGFR inhibitor were rarely more effective). These results suggest that FAK may act as a point of convergence between the integrin and FGFR signaling pathways stimulated by L1 in these cells. CONCLUSIONS: We here show for the first time that small-molecule inhibitors of FGFR, integrins and FAK effectively and selectively abolish L1-stimulated migration and proliferation of glioblastoma-derived cells. Our results suggest that these inhibitors have the potential to reduce the aggressiveness of high-grade gliomas expressing L1.
PURPOSE: The cell adhesion/recognition protein L1CAM (L1; CD171) has previously been shown to act through integrin, focal adhesion kinase (FAK) and fibroblast growth factor receptor (FGFR) signaling pathways to increase the motility and proliferation of glioblastoma cells in an autocrine/paracrine manner. Here, we investigated the effects of clinically relevant small-molecule inhibitors of the integrin, FAK and FGFR signaling pathways on glioblastoma-derived cells to determine their effectiveness and selectivity for diminishing L1-mediated stimulation. METHODS: The effects of the FGFR inhibitor PD173074, the FAK inhibitors PF431396 and Y15 and the αvβ3/αvβ5 integrin inhibitor cilengitide were assessed in L1-positive and L1-negative variants of the humanglioblastoma-derived cell lines T98G and U-118 MG. Their motility and proliferation were quantified using time-lapse microscopy and DNA content/cell cycle analyses, respectively. RESULTS: The application of all four inhibitors resulted in reductions in L1-mediated motility and proliferation rates of L1-positive glioblastoma-derived cells, down to the level of L1-negative cells when used at nanomolar concentrations, whereas no or much smaller reductions in these rates were obtained in L1-negative cells. In addition, we found that single inhibitor treatment resulted in maximum effects (i.e., combinations of FAK or integrin inhibitors with the FGFR inhibitor were rarely more effective). These results suggest that FAK may act as a point of convergence between the integrin and FGFR signaling pathways stimulated by L1 in these cells. CONCLUSIONS: We here show for the first time that small-molecule inhibitors of FGFR, integrins and FAK effectively and selectively abolish L1-stimulated migration and proliferation of glioblastoma-derived cells. Our results suggest that these inhibitors have the potential to reduce the aggressiveness of high-grade gliomas expressing L1.
Authors: Vita M Golubovskaya; Carl Nyberg; Min Zheng; Frederick Kweh; Andrew Magis; David Ostrov; William G Cance Journal: J Med Chem Date: 2008-12-11 Impact factor: 7.446
Authors: Hemant Sarin; Ariel S Kanevsky; Haitao Wu; Alioscka A Sousa; Colin M Wilson; Maria A Aronova; Gary L Griffiths; Richard D Leapman; Howard Q Vo Journal: J Transl Med Date: 2009-06-23 Impact factor: 5.531
Authors: Concha López-Ginés; Lara Navarro; Lisandra Muñoz-Hidalgo; Enrique Buso; José Manuel Morales; Rosario Gil-Benso; Mariela Gregori-Romero; Javier Megías; Pedro Roldán; Remedios Segura-Sabater; José Manuel Almerich-Silla; Daniel Monleón; Miguel Cerdá-Nicolás Journal: Cell Oncol (Dordr) Date: 2017-06-19 Impact factor: 6.730
Authors: Emma Camacho-Urkaray; Jorge Santos-Juanes; Francisco Borja Gutiérrez-Corres; Beatriz García; Luis M Quirós; Isabel Guerra-Merino; José Javier Aguirre; Iván Fernández-Vega Journal: Cell Oncol (Dordr) Date: 2017-12-07 Impact factor: 6.730
Authors: Monica E Burgett; Justin D Lathia; Patrick Roth; Amy S Nowacki; Deni S Galileo; Elena Pugacheva; Ping Huang; Amit Vasanji; Meizhang Li; Tatiana Byzova; Tom Mikkelsen; Shideng Bao; Jeremy N Rich; Michael Weller; Candece L Gladson Journal: Oncotarget Date: 2016-07-12
Authors: Cyntia F Montenegro; Bruna C Casali; Rafael L B Lino; Bianca C Pachane; Patty K Santos; Alan R Horwitz; Heloisa S Selistre-de-Araujo; Marcelo L Lamers Journal: PLoS One Date: 2017-04-24 Impact factor: 3.240
Authors: Amir B Ghaemmaghami; Maryam Mahjoubin-Tehran; Ahmad Movahedpour; Korosh Morshedi; Amirhossein Sheida; Seyed Pouya Taghavi; Hamed Mirzaei; Michael R Hamblin Journal: Cell Commun Signal Date: 2020-08-03 Impact factor: 7.525